RxDoctor Payments Data

Kiritkumar Patel, MD

Cardiovascular Disease · Bloomfield Hills, MINPI 1003871294

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $10,761 of the $17,341 with a category attached, or 62.1%. Medtronic accounts for 64.9% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2019 at $7,639 and has fallen 88.6% since, to $868 in 2025.

$17,341in general payments, 2019–2025

Across 286 payments — averaging $60.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$11K
  • Endologix LLC$1K
  • Abbott$1K
  • Bolton Medical Inc$554
  • Abiomed$487
  • Novartis$304
  • plus $2K from 30 others
$658,633in research payments, 2019–2025

Across 110 payments — averaging $5987.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$589K
  • Shockwave Medical, Inc$39K
  • Boehringer Ingelheim International GmbH$23K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$7K

What the payments were for

  • Travel & lodging$6,49237%
  • Food & beverage$10,76162%
  • Education$140%
  • Other$730%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,341 in reported general payments places this provider in the 80th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$619,380
Medicare patients
1,977
Services billed
6,970

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban856$1,101,483
EntrestoSacubitril/Valsartan444$586,709
JardianceEmpagliflozin231$323,584
FarxigaDapagliflozin Propanediol231$289,532
Repatha SureclickEvolocumab208$214,773
XareltoRivaroxaban122$155,316
Praluent PenAlirocumab96$88,555
BrilintaTicagrelor49$42,935
Atorvastatin Calcium1,851$31,926
ClopidogrelClopidogrel Bisulfate1,326$30,093
Metoprolol Succinate1,405$25,463
Ranolazine ErRanolazine120$16,672
CorlanorIvabradine Hcl15$15,508
Icosapent Ethyl25$12,781
Rosuvastatin Calcium607$11,812

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$82$1,101,483856 claims
NovartisEntresto$304$586,709444 claims
AstraZenecaFarxiga, Brilinta$25$332,467280 claims
Johnson & JohnsonXarelto$55$155,316122 claims
AmgenCorlanor$64$15,50815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Bloomfield Hills

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →